Drug intelligence / Profile preview

C2402

Development stage: Phase 3
Lead developer: JW Pharmaceutical
Administration: Oral

Overview

C2402 is a drug developed by JW Pharmaceutical. It is currently being investigated in a multi-center, randomized, double-blind, parallel, Phase III clinical trial. The trial aims to evaluate the efficacy and safety of C2402, particularly when co-administered with JW0104, in patients diagnosed with hypertension and dyslipidemia. C2402 is administered orally once daily.

Beyond the preview

Go deeper on C2402.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C2402.

Explore the full profile